Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Oncol. 2014 Aug 1;32(22):2296-303. doi: 10.1200/JCO.2013.52.9867. Epub 2014 Mar 31.

Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.

Author information

1
Daniel J. Schaid and Shannon K. McDonnell, Mayo Clinic, Rochester, MN; Colin F. Spraggs and Charles J. Cox, GlaxoSmithKline Research and Development, Stevenage, Hertfordshire; Joan Curran, GlaxoSmithKline Research and Development, London, United Kingdom; Laura R. Parham, GlaxoSmithKline Research and Development, Research Triangle Park, NC; Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; Dianne M. Finkelstein and Paul E. Goss, Massachusetts General Hospital, Boston, MA; and Erica Rappold and Lon R. Cardon, GlaxoSmithKline Research and Development, Philadelphia, PA.
2
Daniel J. Schaid and Shannon K. McDonnell, Mayo Clinic, Rochester, MN; Colin F. Spraggs and Charles J. Cox, GlaxoSmithKline Research and Development, Stevenage, Hertfordshire; Joan Curran, GlaxoSmithKline Research and Development, London, United Kingdom; Laura R. Parham, GlaxoSmithKline Research and Development, Research Triangle Park, NC; Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; Dianne M. Finkelstein and Paul E. Goss, Massachusetts General Hospital, Boston, MA; and Erica Rappold and Lon R. Cardon, GlaxoSmithKline Research and Development, Philadelphia, PA. colin.f.spraggs@gsk.com.

Abstract

PURPOSE:

Liver injury is a serious adverse event leading to permanent discontinuation of lapatinib in affected patients. This study aimed to validate previously associated major histocompatibility complex (MHC) variants as predictors of risk of liver injury by using a large, randomized, placebo-controlled trial of lapatinib in human epidermal growth factor receptor 2-positive, early-stage breast cancer (Tykerb Evaluation After Chemotherapy [TEACH]: Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer).

PATIENTS AND METHODS:

The frequency of ALT elevation cases was compared among four MHC variants in 1,194 patients randomly assigned to lapatinib. Cumulative ALT elevation time courses during treatment were also compared between carriers and noncarriers of specified MHC variants.

RESULTS:

In lapatinib-treated patients, there was a significant difference in ALT case incidence between HLA carriers and noncarriers. The highly correlated alleles HLA-DRB1*07:01 and HLA-DQA1*02:01 (study frequency, 22.4%) were associated with ALT elevation (odds ratio, 14) between cases (n = 37) and controls (n = 1,071). These associations strengthened at higher ALT elevation thresholds and in Hy's Law cases. In lapatinib-treated patients, the overall risk for National Cancer Institute-Common Terminology Criteria for Adverse Events grade 3 ALT elevation (> 5× upper limit of normal) was 2.1%; HLA allele carriers had an increased risk of 7.7%; in noncarriers, risk was reduced to 0.5%, comparable to ALT elevation for all patients receiving placebo. The increase in ALT case incidence in the lapatinib arm showed no evidence of plateau during 1 year of lapatinib treatment.

CONCLUSION:

These results validate HLA-DRB1*07:01 allele carriage as a predictor of increased risk of lapatinib-induced liver injury and implicate an immune pathology. The HLA association could support clinical management of patients experiencing hepatotoxicity during lapatinib treatment.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00374322.

PMID:
24687830
DOI:
10.1200/JCO.2013.52.9867
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center